Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The triple therapy of metformin, a DPP-4 inhibitor and a SGLT-2 inhibitor has a very low treatment related hypoglycaemia risk, leads to a further, almost additive reduction of glycaemic parameters, a body weight loss in the same range as with a mono- or dual therapy with a SGLT-2 inhibitor and also to the expected SGLT-2 inhibitor induced reduction of blood pressure
(Scientific Reports, 2022) showed that the combination of 5-Amino-1MQ + caloric restriction establishes a distinct cecal microbial profile, normalizing the microbiome to the levels of lean control mice, whereas caloric restriction alone fails to do so
PMID: 29313814
Derosa, G., Maffioli, P., Ferrari, I., D'Angelo, A., Fogari, E., Palumbo, I., Randazzo, S., and Cicero, A
Delayed gastric emptying (gastroparesis) or bowel obstruction in rare cases
US$ 27.45
US$ 22.71
US$ 29.85
US$ 24.58
